Case number 1:19-cv-02115
IBSA Institut Biochimique SA et al v. Teva Pharmaceutical USA, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jan 8, 2020 | 12 | Patent/Trademark Report to Commissioner (1) |
| Jan 8, 2020 | 12 | Notice of Voluntary Dismissal (1) |
| Jan 8, 2020 | 13 | Redacted Document (4) Docket Text: REDACTED VERSION of [11] Order by Teva Pharmaceutical USA, Inc.. (Keller, Karen) |
| Jan 8, 2020 | 12 | Main Document (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,691,411 B2; 7,723,390 B2. (Attachments: # (1) Notice of Voluntary Dismissal)(nms) |
| Jan 3, 2020 | N/A | Terminated Case (0) Docket Text: CASE CLOSED per D.I. [10]. (nms) |
| Jan 2, 2020 | 10 | Notice of Voluntary Dismissal (1) Docket Text: NOTICE of Voluntary Dismissal, by Altergon SA, IBSA Institut Biochimique SA, IBSA Pharma Inc. as to Teva Pharmaceuticals USA, Inc.. (Egan, Brian) Modified on 1/2/2020 (nms). |
| Nov 25, 2019 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [8] STIPULATION TO EXTEND TIME to answer, move, or otherwise respond to the complaint to January 2, 2020 (*Reset Answer Deadlines: Teva Pharmaceutical USA, Inc. answer due 1/2/2020). Signed by Judge Richard G. Andrews on 11/22/2019. (nms) |
| Nov 22, 2019 | 8 | Stipulation to EXTEND Time (1) Docket Text: STIPULATION TO EXTEND TIME to answer, move, or otherwise respond to the complaint to January 2, 2020 - filed by Teva Pharmaceutical USA, Inc.. (Fry, David) |
| Nov 13, 2019 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. (rjb) |
| Nov 12, 2019 | 7 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by IBSA Pharma Inc., IBSA Institut Biochimique SA, Altergon SA. Teva Pharmaceutical USA, Inc. served on 11/12/2019, answer due 12/3/2019. (Egan, Brian) |
| Nov 11, 2019 | 6 | Disclosure Statement (2) Docket Text: Amended Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent IBSA Holding SA for IBSA Institut Biochimique SA; Corporate Parent IBSA Institut Biochimique SA for IBSA Pharma Inc.; Corporate Parent - no parent corporation for Altergon SA filed by Altergon SA, IBSA Institut Biochimique SA, IBSA Pharma Inc.. (Egan, Brian) |
| Nov 8, 2019 | 1 | Complaint (7) |
| Nov 8, 2019 | N/A | Summons Issued (0) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Teva Pharmaceutical USA, Inc. on 11/8/2019. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (sam) |
| Nov 8, 2019 | 1 | Exhibit A-B (39) |
| Nov 8, 2019 | 1 | Civil Cover Sheet (1) |
| Nov 8, 2019 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (sam) |
| Nov 8, 2019 | 3 | ANDA Form (1) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: September 26, 2019. Date of Expiration of Patent: March 14, 2024.Thirty Month Stay Deadline: 3/26/2022. (sam) |
| Nov 8, 2019 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,691,411 B2 ;7,723,390 B2 (sam) |
| Nov 8, 2019 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent IBSA Holding SA for IBSA Institut Biochimique SA, IBSA Pharma Inc. filed by Altergon SA, IBSA Institut Biochimique SA, IBSA Pharma Inc. (sam) |
| Nov 8, 2019 | 1 | Main Document (7) Docket Text: COMPLAINT filed against Teva Pharmaceutical USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2774847.) - filed by IBSA Pharma Inc., IBSA Institut Biochimique SA, Altergon SA. (Attachments: # (1) Exhibit A-B, # (2) Civil Cover Sheet)(sam) |
| Nov 8, 2019 | 1 | Complaint* (1) |
